ArticleThe world journal of men's health2026
Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia: An Umbrella Review and Updated Meta-Analysis.
Article in The world journal of men's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeWater vapor thermal therapy (WVTT) is an emerging minimally invasive therapy for benign prostatic hyperplasia (BPH). This umbrella review and updated meta-analysis aims to evaluate the comprehensive outcomes of WVTT for the management of BPH. MATERIALS AND
methodsUp to January 2025, randomized clinical trials and observational studies were included in the updated meta-analysis, while systematic reviews and meta-analyses were included in the umbrella review. Both were conducted in accordance with PRISMA criteria. The umbrella review protocol was pre-registered under registration identifier CRD42024514038. The research compared outcomes including International Prostate Symptom Score (IPSS), peak urinary flow (Qmax), postvoid residual volume (PVR), sexual function, retreatment rates, adverse events and cost-effectiveness. Outcomes were analyzed using a random effects meta-analysis model. The source of heterogeneity was identified by meta-regression.
resultsThe umbrella review comprised 6 systematic reviews and the updated meta-analysis included 25 primary studies involving 3,308 patients. The meta-analysis revealed, at 3 months post-operation, a mean reduction of 10.96 points in IPSS (95% confidence interval [CI], 9.71 to 12.20; I²=89%), a mean increase of 4.70 mL/s in Qmax (95% CI, 4.22 to 5.19; I²=31%), and a mean reduction of 69.52 mL in PVR (95% CI, 52.15 to 86.89; I²=84%). At 12 months, the analysis revealed a mean reduction of 12.35 points in IPSS (95% CI, 10.74 to 13.95; I²=94%), a mean increase of 5.27 mL/s in Qmax (95% CI, 4.46 to 6.07; I²=84%), and a mean reduction of 37.07 mL in PVR (95% CI, 18.29 to 55.85; I²=97%). Our umbrella review showed that WVTT also resulted in low retreatment rates and preserved sexual function. Adverse events were mostly mild and self-limiting.
conclusionsWVTT is an effective and safe treatment for BPH leading to symptom relief with low retreatment rates and wide application scenarios. Clinicians should consider WVTT as a viable minimally invasive alternative for BPH patients who are not suitable for more invasive therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.